Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2012

First GEN TEN Awards for Outstanding Research Presented at BIO

  • The first GEN-sponsored GEN TEN Awards were presented Tuesday to 10 graduate students judged by an independent panel of experts to have submitted the best abstracts on their primary research.

    The awards presentation capped an afternoon “Peer Bash” in which the winners and other graduate students and postdoctoral fellows, and their faculty mentors, engaged in some science and socializing. The event took place at the GEN Theatre (Booth #1211) in the Exhibition Area during the 2012 BIO International Convention at the Boston Convention and Exhibition Center.

    "GEN is proud to recognize the efforts of young scientists and wants to help facilitiate their research and ultimate contributions to the advancement of science and improvement of human health," explained John Sterling, GEN's Editor in Chief. "Each project we selected was exemplary, and I am excited to report on their findings in GEN in the months to come."

    All GEN TEN participants were lauded, each receiving a complimentary subscription to GEN and a Starbucks gift card.

    Congratulations to this year’s honorees:

    • Seemin Seher Ahmed, M.S., of the University of Massachusetts Medical School in Worcester, MA.
    • Ryan Benson, M.S., of Northeastern University.
    • Yanjing Chen, Ph.D., of the University of Rhode Island.
    • Wilfredo E. De Jesus-Monge, M.D., MSc., also of the University of Massachusetts Medical School.
    • Sorin Fedeles, Ph.D., of Yale University.
    • Sanjukta Ghosh Ph.D., of the University of Massachusetts, Boston.
    • Jill Goldstein, M.S., of Yale University.
    • Kevin J. McHugh, B.S., of Boston University.
    • Jenna Sullivan, M.S., of Yale University.
    • Adam Zeiger, of Massachusetts Institute of Technology.


    Watch an interview with two of the winners, Kevin McHugh and Jill Goldstein, at BIOchannel.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »